Lonza Group AG Share Price OTC Markets

Equities

LZAGY

US54338V1017

Biotechnology & Medical Research

Market Closed - OTC Markets 20:59:30 14/06/2024 BST 5-day change 1st Jan Change
53.75 USD -0.20% Intraday chart for Lonza Group AG -3.17% +27.70%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 6.66B 7.48B 590B Sales 2025 * 7.62B 8.56B 675B Capitalization 34.64B 38.9B 3,069B
Net income 2024 * 893M 1B 79.12B Net income 2025 * 1.11B 1.24B 98.08B EV / Sales 2024 * 5.61 x
Net Debt 2024 * 2.72B 3.05B 241B Net Debt 2025 * 3.32B 3.73B 294B EV / Sales 2025 * 4.98 x
P/E ratio 2024 *
38.8 x
P/E ratio 2025 *
31 x
Employees 18,000
Yield 2024 *
0.95%
Yield 2025 *
1.11%
Free-Float 96.79%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.20%
1 week-3.17%
Current month-0.83%
1 month-4.52%
3 months-1.23%
6 months+41.22%
Current year+27.70%
More quotes
1 week
53.44
Extreme 53.44
55.95
1 month
52.23
Extreme 52.23
60.15
Current year
40.14
Extreme 40.1425
62.87
1 year
34.19
Extreme 34.19
64.88
3 years
34.19
Extreme 34.19
86.31
5 years
31.93
Extreme 31.93
86.31
10 years
10.19
Extreme 10.19
86.31
More quotes
Managers TitleAgeSince
Chief Executive Officer 72 24/04/17
Director of Finance/CFO 52 30/11/21
Chief Operating Officer 55 31/07/22
Members of the board TitleAgeSince
Director/Board Member 63 15/04/14
Director/Board Member 66 15/04/14
Director/Board Member 58 04/05/22
More insiders
Date Price Change Volume
14/06/24 53.75 -0.20% 51,668
13/06/24 53.86 -0.37% 24,550
12/06/24 54.06 -2.24% 137,545
11/06/24 55.3 -1.02% 22,720
10/06/24 55.87 +0.65% 15,548

Delayed Quote OTC Markets, June 14, 2024 at 08:59 pm

More quotes
Lonza Group AG is one of the world leaders of the development, production and marketing of chemical products. Net sales break down by family of products and services as follows: - bio-pharmaceuticals (52.6%): exclusive syntheses, microbiological fermentation products , mammalian cell cultures, etc.; - capsules and dosing solutions for biopharmaceuticals, drugs and nutrition products (20.3%). In addition, the group offers nutritional ingredients; - small molecule drug substances (13.2%); - technologies and platforms for manufacturing processes and production of cell and gene therapies (11.1%); - other (2.8%). Net sales are distributed geographically as follows: Switzerland (16%), Europe (29.8%), the United States (38.8%), the Americas (3%), Japan (3.7%), China (2.6%), Asia (5.8%) and other (0.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
480.3 CHF
Average target price
583.7 CHF
Spread / Average Target
+21.53%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW